Kemkes-Matthes Bettina
University of Giessen, Germany.
Semin Thromb Hemost. 2002 Oct;28(5):455-8. doi: 10.1055/s-2002-35286.
Since recombinant hirudin (r-hirudin) has become available, several studies have been published on hirudin for prophylaxis and treatment of thromboembolic complications. Vr-hirudin was shown to be superior even to low-molecular-weight heparin (LMWH) for prophylaxis of deep venous thrombosis (DVT), especially in high-risk patients. Consequently, r-hirudin was expected to be more effective than heparins are in the treatment of thromboembolic events. Vr-hirudin was proved to be safe and efficacious in the therapy of thromboembolic events. However, no benefit could be shown in comparison with heparin. In contrast, in patients suffering from HIT type II, r-hirudin is the drug of choice for the therapy of thromboembolic complications.
自从重组水蛭素（r-水蛭素）问世以来，已经发表了几项关于水蛭素预防和治疗血栓栓塞并发症的研究。在预防深静脉血栓形成（DVT）方面，r-水蛭素甚至被证明优于低分子量肝素（LMWH），尤其是在高危患者中。因此，人们预期r-水蛭素在治疗血栓栓塞事件方面比肝素更有效。r-水蛭素被证明在治疗血栓栓塞事件中是安全有效的。然而，与肝素相比，并未显示出益处。相反，在患有II型肝素诱导的血小板减少症（HIT）的患者中，r-水蛭素是治疗血栓栓塞并发症的首选药物。
